cpt code for autologous stem cell transplant

Sometimes late side effects develop months or years after a stem cell transplant. Side effects can develop any time during, immediately after or a few days or weeks after a stem cell transplant. Side effects can happen with any type of treatment for multiple myeloma, but everyone’s experience is different. A mini transplant is less toxic than an allogeneic transplant with high-dose chemotherapy. This procedure is called a mini-transplant, non-myeloblative or reduced-intensity transplant. Low doses of chemotherapy drugs are sometimes used so that the transplant can be given to older people. People in this age group may also have other health conditions that mean they can’t have an allogeneic transplant with high-dose chemotherapy. The side effects of high doses of chemotherapy used before a stem cell transplant may be too severe for people over 50 years of age. The use of allogeneic stem cell transplant is limited by the need for a matched donor and the side effects, which people over the age of 50 may not be able to tolerate.Īllogeneic stem cell transplants are considered experimental in multiple myeloma and are usually only given in a clinical trial. The donor and recipient are matched through a process called human leukocyte antigen (HLA) typing. The donor may be a relative or may be unrelated to the recipient. In this type of transplant, the stem cells are taken from one person (the donor) and are given to another person (the recipient). A stem cell transplant is a complex procedure that must be done in specialized transplant centres or hospitals. Organ function tests look at how well your organs, such as the liver, kidneys, heart and lungs, are working. Your doctor will base the decision of whether or not to do a stem cell transplant on your age, your general health and the results of organ function tests. if the disease has come back after it has been treated (called relapse) or treatment is no longer working (called refractory treatment).You may be offered a stem cell transplant to treat multiple myeloma: The next step is to get healthy stem cells to replace the ones in the bone marrow destroyed by the chemotherapy. The first step of a stem cell transplant is to get high-dose chemotherapy to kill all of the cells in the bone marrow, including the myeloma cells. All our blood cells develop from blood stem cells. They are basic cells that develop into different types of cells that have different jobs. Stem cells are found in the bone marrow, the bloodstream and umbilical cords. Continued efforts to refine patient selection and management, and incorporate novel anti-plasma cell agents in combination or sequentially to further improve outcomes in AL amyloidosis are also discussed.ĪL amyloidosis Melphalan Patient selection Stem cell transplantation Treatment-related mortality.Some people with multiple myeloma will have a stem cell transplant. This review provides a comprehensive assessment of eligibility criteria, stem cell collection, and mobilization strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies as well as long-term outcome with respect to survival, hematologic response and relapse as well as organ responses following stem cell transplantation. This application has evolved significantly over the past three decades. High-dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in myeloma. AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia.

Cpt code for autologous stem cell transplant